A new study finds multiple sclerosis treatments have long-term benefits, and that early treatment is important. The study is the first to provide evidence that the currently available therapies can delay progression of disability in Multiple Sclerosis. It showed that early treatment — particularly within five years of onset — delayed the secondary progressive stage of MS, which is characterised by an ongoing increase of disability.